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February 10, 2009:526–9ndividuals and defy reasonable adjustment, and BMI use in this
opulation becomes highly questionable.
The “central versus total fat” controversies do not seem firmly
ased, as BMI is not a trustworthy measure of total body fat, and
here is only limited evidence that WC represents some vaguely
efined central “fat compartment.” WC is probably less perturbed
y aging changes, although vertebral compressions can shorten the
runk and “falsely” increase waist measurement. Hip circumference
s affected somewhat by fatness but probably best correlates with
he size of the frame/LBM. Height also correlates with LBM,
ith the noted 20% range of LBM at a given height. Thus, the
atios of WHR and WHtR probably serve as approximate adjust-
ents of WC to individual size. WHtR, an admittedly coarse
easurement, is probably the best available approximation of
verall “fatness,” WF/body weight, for large groups and over broad
anges of age, and was statistically the best model fit (1).
In large populations, almost any reasonable tool, even “eye-
alling,” should provide some approximation of fatness and cor-
elate with fat-related conditions. Behnke (5), who pioneered
uman densitometry, later accommodated to a tape measure and
imple procedures for the practical estimation of body fatness.
ntil improved methods are available, we can best understand
elationships of body composition and future morbidity by appre-
iating the limitations of current anthropometric tools.
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eply
he assessment of clinical usefulness for any measure, and perhaps
articularly for measures of adiposity, relies largely on preference
hen the measures are statistically similar in their associations with
elevant outcomes. While it is true that our study’s results (1) are
ased on analyses of large cohorts, we do not agree that they are
imited in their application to individuals, as suggested by Dr.
reen. In our study, we found that measures of obesity other than
ody mass index (BMI) do not substantially improve statistical
rediction of cardiovascular outcomes. At the same time, we
cknowledged the limitations of BMI, both in misclassifying the
uscular lean and in its deficiency in describing the distribution ofody fat. WThe question then shifts to which measure should be employed
linically. Conveying the risks of obesity to patients in daily clinical
ractice requires, in part, a measure substantiated in standard
efinitions of overweight and obese. While, for a given individual,
hanges in BMI over time will rely on changes in body weight, the
eaning of these changes in weight is often interpreted as progress
oward a healthier goal based on BMI. We do not yet understand
ully how best to target modifications of the waist circumference or
aist-height-ratio, since body fat distribution appears less mallea-
le to change than overall weight. Further study on approaches to
nd benefits of altering body composition and waist circumference
ay clarify these issues.
In our study, we do not advocate a single measure be strictly
mployed in clinical practice. Certainly, for some patients, follow-
ng changes in various anthropometric measures may prove clini-
ally useful in encouraging healthy weight goals. Many patients,
owever, will strive for better health through weight reduction. For
hese individuals, success is defined by a lower BMI, and not by
ther measures.
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eply
rs. Green and Lesser each raise several legitimate and thought-
rovoking issues regarding the article by Gelber et al. (1) and my
ccompanying editorial (2). Their letters highlight several of the
ore important challenges that we face in confronting the obesity
pidemic—first and foremost among these is the very problem of
efining obesity. I concur that there is no single measure of
diposity that is simple to obtain, highly reproducible, widely
vailable, and fully reflective of cardiovascular (or other) risk.
iven this problem, I tried to make a case in the editorial that for
majority of the population, particularly those in the age range
here interventions intended to induce loss of fat are most likely to
e beneficial (younger and middle-age patients), body mass index
BMI) performs nearly as well as waist circumference (or waist/hip
r waist/height). Therefore, until we find a better measure of
atness, I opined that we should continue to use BMI. All that
eing said, I readily agree that BMI has significant limitations as
means to define and quantify obesity.
Dr. Green correctly points out the irresolvable problem of
elating population statistics to the care of individual patients.
hile I agree fully with this point, I believe that the dilemma is
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February 10, 2009:526–9qually applicable to the use of either BMI or waist circumference
s a measure of adiposity and the risk of developing cardiovascular
isease. The fact is that not all patients “at risk” develop disease,
nd not all disease occurs in patients with a known predisposing
isk factor. Regardless of how much we argue about the relative
erits of different risk stratification schemes, at the end of the day,
e are still left with considerable uncertainty in the treatment of
ndividuals.
The condition of “normal weight obesity” characterized by
uscle wasting and abdominal obesity has recently received a lot of
ress. Although this condition certainly exists, it is largely a
roblem of elderly patients. In the elderly population, age itself will
lmost certainly be a more potent risk marker than abdominal
besity. Weight loss in this population may not be of much benefit
n terms of reducing cardiovascular end points. In the middle-age
opulation where application of preventive principles is more likely
o be cost effective, normal weight obesity is uncommon and the
se of a simple metric like BMI will identify the majority of
atients at risk of obesity-related complications. Even though BMI
s an imperfect measure of fatness (particularly visceral fat), it is
lso likely that waist circumference will not be a reliable measure of
isceral fat volume in all patients. Drs. Green and Lesser both
oint out that as clinicians and scientists, we wish to have
nformation about both lean and fat body mass in our patients. I
gree with this sentiment and thank Dr. Lesser for highlighting
he large effect of lean body mass on BMI calculations. Unfortu-
ately, it is difficult or impossible to obtain measures that accu-
ately separate muscle and fat mass in the typical clinical setting.
Interestingly, most obesity researchers have used a single cutoff
or abnormal waist circumferences (102 cm in men and 98 cm in
omen) regardless of height or other measures of overall body size.
t is obvious to all of us that most biological processes do not
ehave as dichotomous variables, but rather as continuous variables
ith varying degrees of abnormality. As such, I suggest that if we
re to adopt metrics of abdominal obesity based on waist circum-
erence, that we use a graded system (i.e., mild, moderate, or
evere) that somehow takes into account body frame size (e.g.,
ormalizing waist to height).
I thank both authors for their letters. I very much welcome and
ncourage open debate and discussion about the topic of obesity.
his extraordinarily important issue that will inevitably consume
ncreasing amounts of our time and health care dollars.
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ercutaneous Coronary
ntervention for Patients With
table Coronary Artery Disease
chömig et al. (1) reported a meta-analysis addressing the mor-
ality in patients with stable coronary artery disease randomized to
edical therapy and coronary intervention involving 17 prospec-
ive studies. The investigators concluded that based on their data,
a PCI-based invasive strategy may improve long-term survival
ompared with a medical treatment-only strategy” (1).
In addition to the numerous flaws of this analysis pointed out
y the accompanying editorial comment (2), the fundamental
imitation lies in the fact that except for the COURAGE
Clinical Outcomes Utilizing Revascularization and Aggressive
rug Evaluation) trial, none of the studies included in this
nalysis applied contemporary medical treatment. Even though
he same can be said about the interventional strategy, the
ifference is that newer medical interventions, such as high-
ose statins, dual platelet inhibition, adequate angiotensin-converting
nzyme inhibition, and beta blockade, have shown in random-
zed prospective trials to reduce the risk of death and/or
onfatal myocardial infarction compared with the standard of
are (3–5), while such randomized trials (including follow-up)
ailed to show reduction of death or myocardial infarction for
ewer interventional therapies, such as bare-metal or drug-
luting stenting (6 –9).
The report by Schömig et al. (1) therefore is misleading and
rrelevant for contemporary medical practice. We should accept
hat the COURAGE trial, despite some limitations, represents the
est evidence currently available for guiding our approach to
atients with stable coronary artery disease.
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